Markets
MNK

Cerulean Pharma (CERU) Worth Watching: Stock Soars 30.6% - Tale of the Tape

Cerulean Pharma Inc. ( CERU ) was a big mover last session with its shares rising nearly 31% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend of the company as the stock has lost over 16% in the past one-month time frame.

This clinical-stage company developing nanopharmaceutical product candidates has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn't been in trend either. Yesterday's sharp climb is encouraging though, so make sure to keep a close watch on this firm in the near future.

Cerulean Pharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Investors interested in the Medical Drug industry may consider better-ranked stocks like Akorn Inc. ( AKRX ), Mallinckrodt plc ( MNK ) and KaloBios Pharmaceuticals, Inc. ( KBIO ). While Akorn and Mallinckrodt sport a Zacks Rank #1 (Strong Buy), KaloBios bears a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CERULEAN PHARMA (CERU): Free Stock Analysis Report

AKORN INC (AKRX): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

KALOBIOS PHARMA (KBIO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MNK

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More